SG11201507168XA - Novel pyrazol derivatives - Google Patents
Novel pyrazol derivativesInfo
- Publication number
- SG11201507168XA SG11201507168XA SG11201507168XA SG11201507168XA SG11201507168XA SG 11201507168X A SG11201507168X A SG 11201507168XA SG 11201507168X A SG11201507168X A SG 11201507168XA SG 11201507168X A SG11201507168X A SG 11201507168XA SG 11201507168X A SG11201507168X A SG 11201507168XA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazol derivatives
- novel
- novel pyrazol
- derivatives
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13158233 | 2013-03-07 | ||
| PCT/EP2014/054107 WO2014135507A1 (en) | 2013-03-07 | 2014-03-04 | Novel pyrazol derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507168XA true SG11201507168XA (en) | 2015-10-29 |
Family
ID=47827068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507168XA SG11201507168XA (en) | 2013-03-07 | 2014-03-04 | Novel pyrazol derivatives |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9512132B2 (en) |
| EP (1) | EP2964646B1 (en) |
| JP (2) | JP6514119B2 (en) |
| KR (2) | KR102369407B1 (en) |
| CN (1) | CN105143220B (en) |
| AR (1) | AR094978A1 (en) |
| AU (1) | AU2014224784B2 (en) |
| BR (1) | BR112015020795B1 (en) |
| CA (1) | CA2897513C (en) |
| CL (1) | CL2015002387A1 (en) |
| CR (1) | CR20150447A (en) |
| CY (1) | CY1118950T1 (en) |
| DK (1) | DK2964646T3 (en) |
| EA (1) | EA027935B1 (en) |
| ES (1) | ES2629751T3 (en) |
| HK (1) | HK1213258A1 (en) |
| HR (1) | HRP20170919T1 (en) |
| HU (1) | HUE034831T2 (en) |
| IL (1) | IL240327B (en) |
| LT (1) | LT2964646T (en) |
| MA (1) | MA38403A1 (en) |
| MX (1) | MX363727B (en) |
| MY (1) | MY176797A (en) |
| NZ (1) | NZ710052A (en) |
| PE (1) | PE20151539A1 (en) |
| PH (1) | PH12015501843A1 (en) |
| PL (1) | PL2964646T3 (en) |
| PT (1) | PT2964646T (en) |
| RS (1) | RS56148B1 (en) |
| SG (1) | SG11201507168XA (en) |
| SI (1) | SI2964646T1 (en) |
| TW (1) | TWI609866B (en) |
| UA (1) | UA118666C2 (en) |
| WO (1) | WO2014135507A1 (en) |
| ZA (1) | ZA201505073B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102369407B1 (en) * | 2013-03-07 | 2022-03-02 | 에프. 호프만-라 로슈 아게 | Novel pyrazol derivatives |
| SI2978755T1 (en) | 2013-03-26 | 2018-03-30 | F. Hoffmann-La Roche Ag | Novel pyridine derivatives |
| HUE035333T2 (en) | 2013-05-02 | 2018-05-02 | Hoffmann La Roche | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
| PE20151977A1 (en) | 2013-05-02 | 2016-01-07 | Hoffmann La Roche | NEW PURINE DERIVATIVES |
| RS58390B1 (en) | 2013-09-06 | 2019-04-30 | Hoffmann La Roche | Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists |
| WO2016149169A1 (en) * | 2015-03-13 | 2016-09-22 | Abbvie Inc. | (indazol-4-yl)hexahydropyrrolopyrrolones and method of use |
| WO2016191935A1 (en) * | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| JP7090037B2 (en) | 2016-06-23 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | New [1,2,3] triazolo [4,5-d] pyrimidine derivative |
| EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| CN113943297A (en) | 2016-06-23 | 2022-01-18 | 豪夫迈·罗氏有限公司 | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors |
| JP6964099B2 (en) | 2016-06-23 | 2021-11-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | New [1,2,3] triazolo [4,5-d] pyrimidine derivatives |
| EP3950920A4 (en) | 2019-03-25 | 2023-02-01 | Nikon Corporation | Cell manipulation device and cell manipulation method |
| KR20230093251A (en) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Antibody fragment against FAP |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
| CN115246832A (en) * | 2022-06-15 | 2022-10-28 | 深圳湾实验室 | Deubiquitinase USP25 and USP28 targeted inhibitors and preparation and application thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2980677A (en) * | 1961-04-18 | Certificate of correction | ||
| US6653304B2 (en) * | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| DE10219435A1 (en) * | 2002-05-02 | 2003-11-13 | Bayer Cropscience Ag | Substituted pyrazolo-pyrimidin-4-ones |
| AR051596A1 (en) * | 2004-10-26 | 2007-01-24 | Irm Llc | CONDENSED HETEROCICLIC COMPOUNDS NITROGENATED AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FOOD DISORDERS |
| WO2009051705A1 (en) | 2007-10-18 | 2009-04-23 | Merck & Co., Inc. | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| WO2010118367A2 (en) * | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| UA111640C2 (en) | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | DERIVATIVES [1,2,3] TRIAZOLO [4,5-d] PYRIMIDINE AS A cannabinoid receptor agonist 2 |
| WO2014005968A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Novel adamantyl derivatives as cannabinoid receptor 2 agonists |
| BR112015009600A2 (en) | 2012-12-07 | 2017-07-04 | Hoffmann La Roche | pyridine-2-amides useful as cb2 agonists |
| WO2014086805A1 (en) | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| SI2928882T1 (en) | 2012-12-07 | 2017-05-31 | F. Hoffmann-La Roche Ag | Pyrazine derivatives as cb2 receptor agonists |
| JP6426618B2 (en) | 2012-12-07 | 2018-11-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Novel pyridine derivative |
| KR102369407B1 (en) * | 2013-03-07 | 2022-03-02 | 에프. 호프만-라 로슈 아게 | Novel pyrazol derivatives |
-
2014
- 2014-03-04 KR KR1020217003979A patent/KR102369407B1/en active IP Right Grant
- 2014-03-04 KR KR1020157024230A patent/KR102217297B1/en active IP Right Grant
- 2014-03-04 UA UAA201509653A patent/UA118666C2/en unknown
- 2014-03-04 SG SG11201507168XA patent/SG11201507168XA/en unknown
- 2014-03-04 PL PL14709590T patent/PL2964646T3/en unknown
- 2014-03-04 SI SI201430259T patent/SI2964646T1/en unknown
- 2014-03-04 ES ES14709590.5T patent/ES2629751T3/en active Active
- 2014-03-04 EA EA201591624A patent/EA027935B1/en not_active IP Right Cessation
- 2014-03-04 LT LTEP14709590.5T patent/LT2964646T/en unknown
- 2014-03-04 PE PE2015001840A patent/PE20151539A1/en active IP Right Grant
- 2014-03-04 PT PT147095905T patent/PT2964646T/en unknown
- 2014-03-04 DK DK14709590.5T patent/DK2964646T3/en active
- 2014-03-04 WO PCT/EP2014/054107 patent/WO2014135507A1/en active Application Filing
- 2014-03-04 MX MX2015011534A patent/MX363727B/en active IP Right Grant
- 2014-03-04 MY MYPI2015702926A patent/MY176797A/en unknown
- 2014-03-04 NZ NZ710052A patent/NZ710052A/en unknown
- 2014-03-04 MA MA38403A patent/MA38403A1/en unknown
- 2014-03-04 RS RS20170653A patent/RS56148B1/en unknown
- 2014-03-04 AU AU2014224784A patent/AU2014224784B2/en active Active
- 2014-03-04 BR BR112015020795-2A patent/BR112015020795B1/en active IP Right Grant
- 2014-03-04 CA CA2897513A patent/CA2897513C/en active Active
- 2014-03-04 EP EP14709590.5A patent/EP2964646B1/en active Active
- 2014-03-04 CN CN201480012444.5A patent/CN105143220B/en active Active
- 2014-03-04 HU HUE14709590A patent/HUE034831T2/en unknown
- 2014-03-04 JP JP2015560654A patent/JP6514119B2/en active Active
- 2014-03-05 AR ARP140100693A patent/AR094978A1/en active IP Right Grant
- 2014-03-06 TW TW103107745A patent/TWI609866B/en active
-
2015
- 2015-07-15 ZA ZA2015/05073A patent/ZA201505073B/en unknown
- 2015-08-03 IL IL240327A patent/IL240327B/en active IP Right Grant
- 2015-08-20 PH PH12015501843A patent/PH12015501843A1/en unknown
- 2015-08-26 CL CL2015002387A patent/CL2015002387A1/en unknown
- 2015-08-27 CR CR20150447A patent/CR20150447A/en unknown
- 2015-09-03 US US14/844,991 patent/US9512132B2/en active Active
-
2016
- 2016-02-04 HK HK16101304.1A patent/HK1213258A1/en unknown
- 2016-10-24 US US15/332,398 patent/US9694012B2/en active Active
-
2017
- 2017-06-14 HR HRP20170919TT patent/HRP20170919T1/en unknown
- 2017-06-16 CY CY20171100638T patent/CY1118950T1/en unknown
-
2018
- 2018-12-06 JP JP2018229203A patent/JP2019055986A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170919T1 (en) | Novel pyrazol derivatives | |
| ZA201505397B (en) | Novel pyrazole derivative | |
| HK1215795A1 (en) | Amatoxin derivatives | |
| SG11201506100XA (en) | Pyridazinone-amides derivatives | |
| SG11201600743WA (en) | Oxoquinazolinyl-butanamide derivatives | |
| SG11201605189YA (en) | Imidazopyrazinone derivatives | |
| IL241293A0 (en) | Novel triazole derivatives | |
| IL241859B (en) | Novel triazole derivatives | |
| HK1213566A1 (en) | Novel tetrazolone derivatives | |
| HRP20180644T1 (en) | Pyrazole derivative |